Enliven Therapeutics Inc.

Stock Chart, Company Information, and Scan Results

$30.05(as of Mar 19, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Enliven Therapeutics Inc. Company Information, Fundamentals, and Technical Indicators

Stock Price$30.05
Ticker SymbolELVN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees60
CountyUSA
Market Cap$1,629.6M

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc. In Our Stock Scanner

As of Mar 20, 2026
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.